CUBIST PHARMACEUTICALS

Health Issues

Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACAs expansion of covered 340B entitiesOngoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints Antibiotic resistance among elderly population Reimbursement issues for antibiotics HR 4187, DISARM, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act

TargetedSENATE · HOUSE OF REPRESENTATIVES

Medicare/Medicaid

Issues related to Medicare reimbursement of antibiotics; H.R. 4187, Developing Innovative Strategy for Antimicrobial Resistant Microorganisms HR 3402 Protecting Access to Medicare Act of 2014 Public Law No: 113-93 In all of the above the specific issues included Medicare offsets that might be applied to prescription drugs